Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Ocedurenone has an attractive efficacy and safety profile and is currently being examined in the Phase III trial, CLARION-CKD, in patients with uncontrolled hypertension and advanced chronic kidney disease |
| Ozempic continues its GLP-1 market leadership with just shy of 46% market share |
| Rybelsus has 12% value market share driven by strong uptake across geographies |
| What I will commit to is obviously that we saw a very clear and positive safety profile from SELECT and no outliers identified |
| The sales growth reflect strong commercial execution with both operating units contributing to a continuous sales growth, driven by increasing demand for our GLP-1 based diabetes and obesity treatments |
| We are pleased that the FDA has granted priority review for the supplemental new drug application |
| Karsten will go through the financial details, but I'm very pleased with our overall performance for the first nine months of 2023 which has enabled us to raise our outlook for the full year |
| Given our extensive scientific and clinical knowledge within metabolic diseases, we are well positioned to advance our understanding of semaglutide potential benefits and associated health complications |
| We have a great momentum of Ozempic that we've had since the launch, and since the inclusion on the reimbursement list and that can drive growth in China |
| That actually means that we expect to see differentiation not only on efficacy, but it also appears to have a potential upside on the safety side specifically on hyperkalemia |
| The increase in gross margin reflects a positive product mix driven by increased sales of GLP-1 based treatments |
| In international operations, obesity care sales are driven by strong Saxenda performance and the Wegovy launches in five international operation countries |
| The global branded anti-obesity market expansion continues with a global volume growth of 94% |
| With 25% sales growth in our Diabetes Care, we are now growing faster than the total market, improving our global diabetes value market share to 33.3% |
| The increase reflects market share gains in both North America operations and international operations |
| The performance in the first nine months of the year has enabled us to raise the outlook for the full year |
| Overall, we're very pleased with the broad market access that we have for Wegovy |
| Nine months into 2023, we are continuing our sales growth momentum which has enabled us to raise the outlook for the full year |
| I hope it's clear from our comments that we are very pleased with the strong momentum we have in our business also underlined with the raised guidance for 2023, and many questions on the coming years, not least the coming year, but we are really focused on fostering innovation based growth strategy and I feel confident in our ability to scale supply to support that |
| One, clinically meaningful benefit across each of the individual MACE components and regardless of BMI category |
| Operating profit increased by 31% measured in Danish kroner and 37% at constant exchange rates reflecting the sales growth |
| In the first nine months of 2023, our sales grew by 29% in Danish kroner and 33% at constant exchange rates, driven by both our operating units |
| We're really excited about FLOW, underlining the attractiveness of semaglutide and we are equally excited that we soon can disclose what SELECT has to show at the upcoming conference at AHA in a matter of a few days |
| In North America operations obesity care sales grew 244% |
| Obesity care sales grew 174% overall |
| Our GLP-1 sales increased 49% driven by North America growing 43%, and international operations growing 60% |
| Within commercial execution, we are pleased to have reached our obesity aspiration of DKK25 billion and our aspiration for diabetes by reaching a global value market share of 1/3 |
| Net profit increased by 47% and diluted earnings per share increased by 49% to DKK13.71 |
| The sales growth was driven by both operating units with North America operations, growing 49% and international operations, growing 17% |
| In general, what we do see in China is an effect of the VPP of course, that's what you mean the insulin sales result, and that is also when you look at an overall IO business point of view that is what is actually dragging down the overall IO insulin growth, but in China Ozempic is going really well |
| Statement |
|---|
| Insulin sales decreased by 7% driven by a 1% decline in international operations and a 24% sales decline in North America operations |
| The sales decrease was driven by a 30% decline in North America operations and a 22% sales decline in international operations |
| Finally, the sales outlook reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies |
| Total rare disease sales decreased 18%, which was driven by 22% decrease in international operations and by a 13% decrease in North America operations |
| Sales of rare endocrine disorder products decreased by 54%, reflecting a temporary reduction in manufacturing output |
| The sales decrease was driven by a decrease in sales in the US and region China |
| This is partially countered by declining sales in rare disease due to a temporary reduction in manufacturing output |
| Our rare disease sales decreased by 18% |
| The inherent uncertainty of the pace of Ozempic -- obesity care market expansion following the re-launch of Wegovy in the US and a limited rollout in international operations are also included in the guidance range |
| While we await data from the SELECT trial to be presented |
| I appreciate the commentary year-to-date, but in the third quarter it seem to trend down quite a bit, which I guess it's somewhat unusual given the quite significant improvements we saw in the gross to nets in your most profitable market for both Wegovy and Ozempic |
| We are hearing that a growing number of employers are having to opt out having already opted in because the demand's been too high |
| There remains a significant need in treatment of hypertension, which is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease, and death |
| These are subject to risks and uncertainties that could cause actual results to differ materially from expectations |
| Just on supply, if we take the sort of run rate for GLP-1 volumes your franchise in the US and just extrapolate into '24, if nothing changes, I mean there's going to be a big disconnect in terms of people's expectations for growth next year and I think will be effectively flat |
| So I'm not really sure what your data source is, but I think my data point is lower than yours in terms of number of new starts per week |
| While supply capacity for Wegovy is gradually being expanded, the lower dose strength in the US will remain restricted to safeguard continuity of care |
| Demand for Wegovy continues to exceed supply, and to safeguard continuity of care for patients already on Wegovy, the supply of the lower Wegovy dose strengths in the US has been reduced since May of 2023 |
| This was partially countered by costs related to ongoing capacity expansions, and negative currency impact, and lower realized prices mainly in the US and Region China |
| So just very quickly as we think about the SELECT trial results in the wake, not just of the presentation, but the very rapid filing, there had been a lot of questions around this being actually a cardiovascular medication and perhaps gaining access to CMS in that regard |
Please consider a small donation if you think this website provides you with relevant information